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1. Introduction 
The genetic information stored in DNA can be transcribed and translated into functional 
proteins with various biological roles, and the control of gene expression and cell division is 
tightly controlled under normal physiological conditions. However, genetic mutations 
arising during DNA replication can trigger uncontrolled cell growth, leading to the 
development of various types of cancers (Croce 2008). The cellular transformational events 
associated with cancer have been linked with mutations in particular genes, termed proto-
oncogenes. These genes are necessary for the normal development and differentiation of 
cells, but when mutated into oncogenes they can lead to the overexpression of proteins 
involved in signal transduction and mitosis, ultimately resulting in cancer development. 
Blocking oncogenic translation using siRNAs has attracted intense attention in the literature 
(Heidenreich 2009; Ventura et al. 2009), but inhibiting oncogenic transcription through 
targeting DNA itself has been less explored. 
While DNA is a well-established biomolecular target for anti-cancer therapy, most DNA-
binding drugs such as cisplatin (Alderden et al. 2006) and its analogues interact with DNA 
non-selectively, resulting in adverse side effects (Jung et al. 2007). Consequently, this has 
driven interest in the targeting of unusual, non-canonical structures in DNA, in order to 
achieve selectivity for particular (onco)genes while potentially reducing adverse side effects. 
One such DNA structure that has attracted significant attention in the recent literature as an 
anti-cancer target is the G-quadruplex. While G-quadruplexes were initially regarded as 
somewhat of a structural curiosity when they were first discovered, accumulating evidence 
over the past decade have suggested that these non-canonical DNA structures may play 
important roles in modulating various biological processes (Lipps et al. 2009). 
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G-quadruplexes are four-stranded guanine-rich DNA structures that were first found at the 
ends of eukaryotic telomeres, and the role of telomeric G-quadruplexes for inhibiting 
telomerase activity has been intensely studied since the early 1990s (Blackburn 1991). 
Human telomeric DNA is usually 4–14 kilobases long, and is comprised of TTAGGG 
tandem repeats. Up-regulated telomerase activity in cancer cells maintains the length of 
telomeres after cell division, conferring immortality. Hurley and co-workers demonstrated 
that the activity of telomerase can be inhibited by small molecule-induced stabilization of 
telomeric G-quadruplex (Wheelhouse et al. 1998).  
A few years later, Hurley and co-workers reported the seminal discovery of a potential G-
quadruplex structure in the nuclease hypersensitive element III1 (NHEIII1) of the promoter 
region of the c-myc oncogene, and they further demonstrated that the transcriptional 
repression of c-myc can be achieved by induction of putative G-quadruplex formation by a 
small molecule (Siddiqui-Jain et al. 2002). Evidently, c-myc transcription was inhibited by 
the putative formation of the G-quadruplex structure in the promoter region, thus 
suppressing oncogenic expression. Later, other studies identified the presence of G-
quadruplex-forming sequences in the promoter regions of other oncogenes such as c-kit 
(Rankin et al. 2005), KRAS (Cogoi et al. 2006), bcl-2 (Dai et al. 2006) and VEGF (Jiang et al. 
1991). In 2007, Huppert and Balasubramanian conducted a large-scale bioinformatics 
analysis throughout the human genome, and found that G-quadruplex-forming sequences 
are enriched in the promoter regions of genes, and that >40% of annotated genes bears at 
least one potential G-quadruplex sequence within 1kb of the transcription start site 
(Huppert et al. 2007). Recent evidence has suggested that G-quadruplexes may exist in vivo 
and may play putative roles in various biological processes, such as the regulation of gene 
expression (Dexheimer et al. 2009; Gonzalez et al. 2009). Consequently, targeting the 
oncogenic G-quadruplexes using small molecules has emerged as an alternative strategy for 
the potential treatment of cancers (Balasubramanian et al. 2009).  
Since the discovery of the first c-myc G-quadruplex stabilizer TMPyP4 and inhibitor of c-myc 
oncogenic expression by Hurley and co-workers, many other c-myc interactive small 
molecule ligands have been identified. For example, cationic porphyrins (Grand et al. 2002), 
quindoline and berberine derivatives (Ou et al. 2007; Lu et al. 2008; Ma et al. 2008), and 
trisubstituted isoalloxazines (Bejugam et al. 2007) have been demonstrated to interfere with 
the oncogenic transcription in vitro. Quarfloxin, developed by Cylene Pharmaceuticals, 
entered clinical trials due to its ability to interact with G-quadruplexes in vivo (Duan et al. 
2001). Interestingly, quarfloxin concentrates in the nucleus and disrupts the G-quadruplex-
nucleolin interaction, leading to the redistribution of nucleolin in the nucleoplasm which 
ultimately triggers the apoptosis and inhibition of cancer cell growth. 
With advances in computer processing power and in the development of algorithms for 
molecular stimulation and docking, the use of high-throughput virtual screening for drug 
discovery has become increasingly popular (McInnes 2007). The rapid screening of a large 
chemical library using computational programs can efficiently weed out non-binding 
ligands in silico, thus dramatically reducing the number of compounds to be tested in vitro. 
While the use of computer-aided virtual screening for discovering enzyme antagonists has 
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been widely employed, the use of computational analysis for identifying G-quadruplex 
ligands has been comparatively less explored (Ma et al. 2012). In this chapter, we first 
describe the general structure of G-quadruplexes and their involvement in transcriptional 
events, particularly those relevant to oncogenic expression. We then discuss the use of in 
silico methods to identify small molecule ligands of oncogenic promoter G-quadruplexes, 
and identify features or limitations of each method. Finally, we highlight recent, 
representative, examples of promoter G-quadruplex targeting by small molecules 
discovered using in silico methods.  
2. General structure of the G-quadruplex and its involvement in 
transcriptional events  
G-quadruplexes are constructed from stacks of G-tetrads, which consist of four guanine 
bases aligned in a co-planar arrangement stabilized by Hoogsteen hydrogen-bonding and 
monovalent cations (e.g. K+ and Na+) in the central cavity (Figure 1) (Mergny et al. 1998; 
Parkinson et al. 2002; Huppert et al. 2007). G-quadruplexes exhibit a high degree of 
structural polymorphism, contributing to the wide variety of distinct G-quadruplex 
topologies that differ in strand orientation, loop size, surface and groove dimensions (Burge 
et al. 2006). Consequently, G-quadruplexes formed from different DNA sequences may 
exhibit unique structural features that can be specifically targeted by small molecule ligands 
(Monchaud et al. 2008). 
 
Figure 1. The structure of a G-tetrad stabilized by Hoogsteen hydrogen bonding and a monovalent 
cation resided in the central channel (left). Some possible topologies for an intramolecular G-
quadruplex (right). 
As previously mentioned, the occurrence of G-quadruplex-forming regions in the promoter 
region of oncogenes offers an alternative therapeutic avenue for the treatment of cancer. The 
induction of the G-quadruplex structure in the promoter region of the target gene could 
inhibit transcription of the oncogene, thus suppressing the production of the resultant 
oncoprotein. The potential to repress oncogenic expression by G-quadruplex formation can 
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be illuminated by considering the history of the efforts targeted against well-studied 
oncogene c-myc.   
 
Figure 2. Transcription regulation of oncogenes by promoter G-quadruplex formation mediated by 
small molecules (circle). 
MYC protein is a transcription factor that controls cell proliferation, differentiation and 
apoptosis (Marcu et al. 1992), and its cellular level is strictly regulated in normal cells. 
Mutation of c-myc and the overexpression of the MYC protein are observed in around 80% 
of solid tumors, including cervical carcinoma, myeloid leukemias and osteosarcomas (Lutz 
et al. 2002; Meyer et al. 2008; Wierstra et al. 2008). Accumulating evidence has revealed that 
the c-myc promoter region plays a pivotal role in the regulation of c-myc transcriptional 
activity. In particular, the nuclear hypersensitivity element III1 (NHE III1), a 27 bp guanine 
rich sequence located upstream of the c-myc protein, has been reported to control around 
90% of c-myc transcription (Davis et al. 1989). In vitro experiments suggested that this 
sequence is able to fold into an intramolecular parallel G-quadruplex with predominant 
1:2:1 and 2:1:1 loop topologies (Seenisamy et al. 2004). Hurley and co-workers showed the 
basal transcription activity of c-myc can be significantly enhanced by destabilizing the c-myc 
G-quadruplex through a guanine-to-thymine mutation in the quadruplex-forming sequence 
(Siddiqui-Jain et al. 2002). In the same report, they demonstrated the suppression of 
oncogenic c-myc transcription activity by a cationic porphyrin that can stabilize the G-
quadruplex structure (Siddiqui-Jain et al. 2002). These results demonstrated that the c-myc 
promoter G-quadruplex may act as a regulator of oncogenic transcription, and that small 
molecule stabilizers of the G-quadruplex could potentially down-regulate the expression of 
oncogenes (Figure 2).  
These promoter G-quadruplex-stabilizing ligands have potential advantages as alternative 
anti-cancer compounds compared to conventional protein or enzyme inhibitors 
(Balasubramanian et al. 2011). Firstly, since the availability of G-quadruplexes in cells is 
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generally limited, a lower concentration of inhibitor could theoretically be used to achieve 
the desired biological effect. Secondly, due to the unique structural diversity of G-
quadruplex motifs, superior selectivity towards a particular G-quadruplex may be 
potentially achieved by the rational design and modification of the lead compound. Thirdly, 
a number of oncogenes such as c-kit, BRAF and c-myc, which have been reported to contain 
G-quadruplex-forming motifs in their promoter regions, encode kinase or protein products 
that have been clinically validated as targets for the treatment of cancer. However,  a 
number of issues remain for the development of effective promoter G-quadruplex ligands 
for the treatment of human diseases. These include acquiring more detailed and 
comprehensive structural information on the relevant topologies of G-quadruplexes in 
living systems, as well as developing ligands with sufficient G-quadruplex selectivity and 
affinity for potential in vivo application. Leading experts Balasubramanian, Hurley and 
Neidle have recently reviewed the targeting of oncogenic promoter G-quadruplexes as a 
potential anti-cancer strategy (Balasubramanian et al. 2011).  
3. In silico methods in drug discovery 
Virtual screening techniques have recently emerged as a complementary technique to 
traditional high-throughput screening technologies employed in the pharmaceutical 
industry (Shoichet 2004; Ghosh et al. 2006; Cavasotto et al. 2007). Using computer-aided 
methodologies, large numbers of compounds can be rapidly screened in order to efficiently 
eliminate non-binding compounds in silico, thus dramatically reducing the costs associated 
with preliminary testing in a drug discovery project. However, while the application of in 
silico techniques for discovering enzyme inhibitors has been well-established, the targeting 
of DNA structures using virtual screening has been comparatively less explored. Broadly 
speaking, virtual screening can be sub-divided into pharmacophore modelling and 
molecular docking. A representative list of commercially available molecular docking 
softwares for both pharmacophore modelling and molecular docking (receptor-ligand 
modelling) is given in Table 1. 
Pharmacophore modelling can be further classified into structure-based and ligand-based 
methods. In structure-based pharmacophore modelling, the structure of receptor must be 
first determined using techniques such as X-ray crystallography and nuclear magnetic 
resonance (NMR). Alternatively, if the structure of particular target is not known, a model 
can be constructed by homology with closely-related structures. In general, a structure 
containing the biomolecular target complexed with its ligand is advantageous for virtual 
screening since the key features of the interaction between the ligand and the binding pocket 
can be directly examined. Some commercially available computational software programs 
such as LIGANDSCOUT (Wolber et al. 2004) and POCKET v.2 (Chen et al. 2006) are able to 
analyse the binding interaction and calculate the relevant contributions of each feature to the 
specificity and inhibitory potency of the ligand. Ligand–target interactions can include 
hydrogen bonding, ionic interactions and hydrophobic interactions, and this information 
can be harnessed to generate a three-dimensional (3D) pharmacophore model.  
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Company/Institution Software Uses
Accelrys Discovery Studio, 
Insight II 
Pharmacophore modelling, receptor-
ligand docking, de novo drug design, 
molecular stimulation 
MolSoft ICM-Pro Pharmacophore modelling, receptor-
ligand docking, 3D QSAR model 
constructions  
Tripos Sybyl Receptor-ligand docking, 
chemoinformatics, 3D QSAR model 
constructions 
Scripps Research 
Institute 
Autodock Receptor-ligand docking 
Schrodinger Phase Receptor-ligand docking, 
pharmacophore modelling 
Table 1. Examples of commercially available drug discovery softwares. 
In contrast, a prior knowledge of the biomolecular target is not needed in ligand based 
pharmacophore modelling, but instead a library of compounds with known potencies 
towards the biomolecular target is required for the construction of a training set. In silico 
techniques are then employed to generate a 3D pharmacophore that bears the representative 
electronic and steric features of the compounds from the training set. To obtain a reliable 3D 
pharmacophore, the training set should include structurally diverse compounds with in 
vitro potencies spanning a few orders of magnitude.  
To confirm the validity of the 3D pharmacophore generated from either structure-based or 
ligand-based pharmacophore modelling, cost analysis techniques can be carried out based 
on statistical calculations in order to generate the “best” hypothetical structure. The 
validated pharmacophore is then subjected to virtual screening from chemical libraries to 
identify molecules that possess similar steric and electronic features with the 
pharmacophore. However, a drawback of pharmacophore modelling is that since the 
affinity calculation only involves the matching of geometry and functional groups of the 
potential ligand with the 3D pharmacophore, the screening process will tend to reveal 
ligands that structurally and electronically resemble the training set of compounds, rather 
than uncovering novel hit scaffolds. 
On the other hand, molecular docking represents a totally different approach for virtual 
screening of bioactive compounds. Molecular docking involves stimulating the interactions 
between biomolecules and the ligands by computational algorithms. Molecular modelling 
has been gaining in popularity due to the increasing availability of biomolecular structures 
determined by either X-ray crystallography or NMR. In addition, advances in computational 
power and the continual development of more refined docking algorithms help to mitigate 
the relatively high computational strain demanded by molecular docking. In molecular 
docking, knowledge of the 3D biomolecular structure is essential, with or without the 
binding ligand. As previously described, the use of a biomolecular structure co-crystallized 
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with a ligand is preferred as the binding pocket of the ligand can be easily identified and the 
subsequent docking analysis can then be restricted to the areas around the binding pocket in 
order to avoid wastage of computational resources and to eliminate false positives that 
interact outside of the binding site. 
After completion of a virtual screening campaign, the resulting hit list of compounds can be 
subjected to experimental assays for hit validation (Figure 3). Alternatively, the hit 
structures can be used to construct analogues that can be screened in silico to potentially 
generate more potent ligands before chemical synthesis and biological testing.  
 
Figure 3. Pipeline of computer-aided drug discovery and lead optimization processes. 
4. Molecular docking to discover promoter G-quadruplex stabilizing 
ligands 
In order to drive the development of more potent and selective ligands targeting promoter 
G-quadruplexes, it is important to understand the detailed interactions between the G-
quadruplex and the ligand at the molecular scale. Molecular modelling can provide a tool 
for visualizing the three-dimensional interactions of the G-quadruplex-ligand complex in 
order to better understand the structural or functional features required for effective 
binding. Compared to pharmacophore-based methods, molecular docking can potentially 
make more effective use of the structural information of the receptor for the discovery of 
novel G-quadruplex-targeting compounds. In particular, high-quality structural data on the 
distinctive features of different promoter G-quadruplexes may aid the design and 
optimization of bioactive ligands that are able to discriminate between related G-
quadruplex topologies. In this section, we give a general overview for the in silico structure-
based discovery of oncogenic promoter G-quadruplex stabilizing ligands.  
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Computer-aided high-throughput molecular docking and hit validation usually involves 
three stages (Tang et al. 2006). The first stage is the construction and preparation/selection of 
the chemical library, and the preparation of the biomolecular model for molecular docking. 
The second stage is the docking of the individual compounds of the chemical library against 
the biomolecule, followed by score calculation. In the third stage, the high-scoring 
compounds can be selected for in vitro biological assays to validate their activities towards 
the biomolecular target. 
4.1. Selection of chemical library  
A poorly-designed chemical library can result a high rate of false positives, or otherwise 
poor-quality hits. Therefore, the careful selection of a chemical library containing members 
possessing favourable pharmacokinetic properties (absorption, distribution, metabolism, 
excretion, and toxicity; ADMET) or structural diversity could improve the hit rate of a single 
docking campaign. Today, most chemical libraries are focused in some way by applying a 
manually selected pre-filter. For example, the Lipinski rule-of-five is a common filter that 
represents a collection of structural properties correlated with desirable solubility and 
bioavailability of small molecules (Lipinski et al. 2001). Screening compounds libraries with 
a pre-filter reduces the likelihood of identifying hit compounds with undesirable ADMET 
properties, therefore minimizing any loss of investment in chemical synthesis or biological 
assays. Two types of chemical libraries commonly chosen for virtual screening campaigns 
are drug/drug-like databases and natural product libraries. 
 
Name Company Size of library URL
ChEMBL European Bioinformatics 
Institute (EBI) 
>1.1 million https://www.ebi.ac.uk/chem
bl/ 
ZINC Bioinfomatics and 
Chemical Informatics 
Research Center (BCIRC) 
>21 million http://zinc.docking.org/ 
IBS Database InterBioScreen Ltd >45000 http://www.ibscreen.com/na
tural.shtml 
NatDiverse Analyticon Discovery >20000 http://www.ac-
discovery.com 
Super Drug 
Database 
Humboldt-University ~3000 http://bioinf.charite.de/super
drug/ 
DrugBank  University of Alberta 6711 http://www.drugbank.ca/ 
Table 2. Examples of commercially available chemical libraries used in computer-aided drug 
discovery. 
Approved drugs usually have favourable or validated pharmacokinetic properties and 
toxicological profiles, which can improve the hit rate of the screening campaign, and could 
allow promising hit compounds to potentially bypass early-stage testing, thus streamlining 
the hit-to-lead optimization process. However, the use of an existing drug library for virtual 
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screening cannot uncover novel bioactive compounds against the biological target. On the 
other hand, natural products represent the largest class of compounds in the chemical 
world. The interactions of natural products with biomolecules have been refined throughout 
evolutionary timescales, and these unique interactions can be harnessed by medicinal 
chemists to discover potential drugs. Since most natural products do not strictly adhere to 
Lipinski rule-of-fives, the virtual screening of natural product libraries can yield novel 
bioactive scaffolds that could not be obtained from drug-like or combinatorial libraries. 
Examples of commercially available drug databases and natural product libraries that can 
be used in high-throughput virtual screening are shown in Table 2. 
4.2. Receptor preparation 
To construct the receptor model for molecular docking, the atomic coordinates of G-
quadruplex solved by the X-ray crystallography and NMR studies with or without bound 
ligand can usually be retrieved from the Protein Data Bank (Berman et al. 2000) or Nucleic 
Acid Database (Berman et al. 1996). Generally, structural data obtained from X-ray 
crystallography is considered more advantageous compared to those from solution NMR 
studies, as more detailed structural information can be obtained at the atomic scale. For G-
quadruplexes lacking hard structural data, a model can be constructed by homology by 
modification of known, related G-quadruplex structures determined by X-ray 
crystallography. Commercially available software such as Discovery Studio (Accelrys Inc.) 
or ICM-Pro (Molsoft) can perform modification of the G-quadruplex conformation or 
topology through the addition or deletion of nucleobases, addition of monovalent cations in 
the central ion channel, or modification of the loop length and/or addition of nucleotides in 
the loop region (Lee et al. 2010).  
4.3. G-quadruplex flexibility 
The receptor model prepared can then be subjected to local energy minimization to generate 
the most suitable conformer for subsequent molecular docking analysis. While the small 
molecule ligands are usually assumed to be flexible so that the binding geometry of the 
ligand can be corrected predicted, the target is usually assumed to be mostly rigid, as the 
explicit treatment of receptor flexibility in the docking calculations would be too 
computationally expensive. Several approaches have been proposed to account for receptor 
flexibility in virtual screening campaigns. In the case of the G-quadruplex, the flexibility of 
the loop regions could be important especially for G-quadruplex groove-binding ligands.  
An early approach tackling the problem of receptor flexibility was the “soft-docking” 
method (Jiang et al. 1991). In this approach, the compounds need not fit perfectly to the 
binding pocket of receptor and a certain degree of steric crash is allowed. During the 
docking process, the ligand and the receptor adjust their conformations continuously in 
order to achieve the most suitable conformation with maximum interaction. However, this 
method only utilizes a single receptor conformation, and thus the choice of receptor model 
for docking is of the utmost importance.  
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An alternative strategy that may be useful in G-quadruplex ligand discovery is the use of 
multiple receptor conformations (MRC) to probe the receptor flexibility (Totrov et al. 2008). 
This could involve a combination of multiple structures experimentally determined by X-ray 
crystallography or NMR, or could be generated by molecular stimulation (MD). By 
considering the different receptor features from multiple conformations, a more 
representative receptor conformation could be generated for virtual screening. Some 
modern docking algorithms are able to explicitly model receptor flexibility, but this is 
usually constrained to the ligand binding domain in order to conserve computing resources. 
A more thorough discussion of the common approaches used to model receptor flexibility 
can be found in review articles by Kavraki and co-worker (Teodoro et al. 2003), and Durrant 
and co-worker (Durrant et al. 2010). 
4.4. Global energy optimization 
The compounds from the chemical libraries are docked to the receptor structure 
individually. Generally, assigning the docking site across the entire G-quadruplex structure 
yields end-stacking compounds as the highest-scoring hits. For discovering groove-binders, 
which typically display weaker binding affinities, the search area for docking can be limited 
to the groove or loop regions of the G-quadruplex. Once the compound has been docked 
into the receptor, most computer algorithms will perform global energy optimization of the 
small molecule inside the binding pocket to find the most favourable orientation of the small 
molecule (Abagyan et al. 1994). For example, ICM-Pro (Molsoft) docking software (Abagyan 
et al. 1997) includes the following steps for global energy optimization: 
1. A random conformational change of free variables according to a predefined 
continuous probability distribution. 
2. A local energy minimization of analytical differentiable terms. 
3. A calculation of the complete energy including non-differentiable terms such us 
entropy and solvation energy. 
4. An acceptance or rejection of the total energy based on the Metropolis criterion and a 
return to the first step. 
4.5. Score assignment 
After the global energy optimization, score assignment is then performed to rank the 
compounds according to their predicted binding affinities. The score is a qualitative 
parameter that reflects the binding strength of the compound to the receptor and is 
composed a collection of factors such as hydrophobic interactions, van der Waal 
interactions, hydrogen bonding, and electrostatic interactions. However, the accuracy of the 
docking score will necessarily be limited by the assumptions and approximations of the 
scoring function. Other factors which may not be explicitly predicted by the computational 
algorithms, such as solvent environment and binding pocket availability, could also 
influence the actual binding affinity of the ligand.  
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Different docking programs may employ different scoring functions, which are generally 
classified into the following types: 1) force-field functions; 2) knowledge-based scoring 
functions; and 3) empirical scoring functions (Kitchen et al. 2004). These scoring functions 
perform calculations that involve different parameters such as statistical potential and 
weighted interaction terms to rank the apparent potency of the compounds. To improve the 
accuracy of the scoring assignment, the consensus scoring approach has been investigated. 
This strategy involves the combination of the weighted scores obtained for a single ligand 
from different score functions, to improve the hit rate of a docking campaign (Charifson et 
al. 1999; Clark et al. 2002; Baber et al. 2005; Yang et al. 2005). 
5. Structure-based lead optimization 
In the conventional drug discovery, validation of a screening hit by in vitro assays is usually 
followed by the synthesis of a range of structurally related analogues in order to optimize 
the binding and selectivity of the ligand towards the target. However, this approach 
necessarily entails a significant investment into manpower and materials, and can be very 
time-consuming. An alternative strategy utilizes the principles of computer-aided structure-
based design in order to achieve the more efficient allocation of resources towards 
analogues with higher predicted binding affinities. By analysis of the receptor-ligand 
complex determined using X-ray crystallography or molecular modelling, a library of 
derivatives can be generated in silico that retain the important features of hit ligand that 
contribute to high binding affinity. This focused library can then undergo a second round of 
molecular docking procedure to identify the most promising derivatives for synthesis and 
evaluation.. The application of in silico structure-based optimization has also been applied 
for the development of oncogenic promoter G-quadruplex stabilizing ligands.  
6. Discovery of oncogenic promoter G-quadruplex-stabilizing ligands 
using structure-based approaches 
The use of in silico virtual screening to discover promoter G-quadruplex-stabilizing ligands 
has only been recently reported. Tang and co-workers utilized ligand-based pharmacophore 
modelling techniques to identify two non-planar alkaloids as groove binders of the parallel 
G-quadruplex (Li et al. 2009). In their report, the representative pharmacophore was 
constructed using the CATALYST software package (version 4.11, Accelrys Inc.) (Nicklaus 
et al. 1997). A total of 38 1,4-disubstituted anthraquinone derivatives comprised the training 
set, with IC50 values against rat glioma C6 cells spanning three orders of magnitudes (from 
0.07 mM to 103 mM). Ten hypothetical models were constructed using the HypoGen 
hypothesis process, with the best pharmacophore containing one hydrogen bond receptor, 
one hydrogen bond donor, one positive ionizable group and two hydrophobic sites. The 
best pharmacophore model was selected for virtual screening and was mapped against a 
natural product database containing ca. 10,000 compounds derived from Chinese herbal 
medicines. A total of 176 hit compounds were identified with a diversity of scaffolds 
different to those of the training set, and 20 compounds were chosen for further evaluation 
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based on compound availability. Intriguingly, the hit compounds included two neutral non-
planar compounds, peimine (1) and peimimine (2). In UV melting experiments, peimine (2) 
and peimimine (3) were found to stabilize the tetramolecular G-quadruplex motif with 
significant increases in Tm. Further experiments indicated that both compounds were 
selective for parallel G-quadruplexes, and did not stabilize other G-quadruplex topologies 
or duplex DNA. Circular dichroism (CD) experiments found that compound 1 was able to 
enhance the characteristic parallel G-quadruplex CD signal at 262 nm of all the parallel G-
quadruplexes examined, including c-kit oncogenic promoter G-quadruplex. The study from 
Tang and co-workers demonstrated the feasibility of employing ligand-based 
pharmacophore modelling to identity novel oncogenic promoter G-quadruplex-stabilizing 
compounds. However, further research would be required to fully characterize the possible 
biological effects of the compound in living cells.  
In 2010, our group has employed high-throughput virtual screening techniques to identify 
fonsecin B (3) as a c-myc G-quadruplex stabilizer (Lee et al. 2010). Since no X-ray structure of 
the c-myc G-quadruplex was available, a molecular model of the predominant 1:2:1 loop 
isomer of c-myc G-quadruplex was constructed using the X-ray crystal structure of the 
related intramolecular human telomeric G-quadruplex. The model was built by the insertion 
or deletion of nucleobases and modification of the loop size to correspond to the 1:2:1 loop 
isomer of the c-myc G-quadruplex (Ou et al. 2007) using ICM-Pro (Molsoft). After the 
preparation of the receptor model, over 20,000 compounds from a natural product library 
were docked against the molecular model using the Molsoft ICM-Pro (3.6.1 d) docking 
protocol. Since most G-quadruplex stabilizing ligands possess a large polyaromatic scaffold 
for end-stacking, the docking area to the termini of the G-quadruplex was restricted to avoid 
the wastage of computational time. From the results of the virtual screening campaign, four 
hits were identified and tested in a preliminary in vitro PCR stop assay to assess their 
abilities to stabilize the c-myc G-quadruplex, and fonsecin B (3) emerged as the top 
candidate.  
A variety of experiments were performed to analyze the interaction and selectivity of 
fonsecin B towards the c-myc G-quadruplex. UV-visible absorption spectroscopy revealed 
that compound 3 displayed 5.5-fold and 16.5-fold higher binding affinities for the c-myc G-
quadruplex over duplex and single-stranded DNA, respectively. We then performed a 
detailed molecular modelling experiment in order to investigate the binding mode of the 
compound to the c-myc G-quadruplex. The modelling results revealed that 3 was stacked 
against the 3ʹ-terminal of G-quadruplex with a binding energy of –48 kcal mol–1. The 
phenolic and carbonyl oxygen atoms were predicted to orientate towards the central ionic 
channel, where the two oxygen atoms could possibly be stabilized by electrostatic 
interactions with the potassium ion. By comparison, intercalation of 3 into the G-quadruplex 
was calculated to be extremely unfavourable, with a binding energy of ca. 25 kcal mol–1. PCR 
stop assays showed that 3 was able to stabilize the c-myc G-quadruplex with the similar 
potency to the well-known G-quadruplex ligand TmPyP4.  
Apart from the high-throughput virtual screening of chemical libraries, structure-based 
optimization by in silico approaches have also been employed to improve the potency of the 
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lead compounds to a particular oncogenic promoter G-quadruplex target. In 2009, Che and 
co-workers developed a series of Pt(II) complexes as c-myc G-quadruplex stabilizing ligands 
using an in silico structure-based optimization strategy (Wu et al. 2009). Among a series of 
Pt(II)-salphen complexes tested in preliminary in vitro assays, complex 4 was found to be 
most potent and was chosen for in silico structural modification. Over 60 derivatives of 
complex 4 were designed that contained side chains with various lengths and functional 
groups to interact with the grooves of the G-quadruplex, and these compounds were docked 
to the c-myc G-quadruplex using the ICM program. In the molecular docking analysis, the 
highest scoring compound 5 was found to bind more favorably to the c-myc G-quadruplex 
compared to the parent complex 4 due to the additional interactions between the side chains 
of 5 with the G-quadruplex grooves regions. Compound 5 was then synthesized for 
biological evaluation, and the PCR stop assay results showed 5 could stabilize the formation 
of the c-myc G-quadruplex with an IC50 value of 4.4 µM, which was an order lower than that 
of parent compound 4. In this report, Che and co-workers successfully demonstrate the use 
of structure-based optimization of a Pt(II)-salphen complex to devise a more promising 
scaffold for stabilization of the c-myc oncogenic promoter G-quadruplex.  
 
Figure 4. Structures of promoter G-quadruplex-targeting compounds discovered via high-throughput 
virtual screening. 
Later, the Che group reported another successful application of computer-based lead 
optimization of Pt(II) metal complexes to discover efficient c-myc G-quadruplex stabilizing 
ligands (Wang et al. 2010). Based on hit complex 6, over 550 derivatives were designed by 
attaching side chains of various lengths and functionality to the parent scaffold, the library 
of compounds were rapidly screened in silico. Three of the highest scoring complexes 7–9 
were then synthesized and subjected to comprehensive in vitro assays to evaluate their 
ability to stabilize the c-myc G-quadruplex. In the UV-Vis absorption experiments, all three 
complexes showed at least 10-fold higher binding affinities towards the c-myc G-quadruplex 
over duplex DNA. Furthermore, the complexes increased the Tm of the c-myc G-quadruplex 
by over 9 °C, and displayed improved potency at stabilizing the c-myc G-quadruplex in the 
PCR stop assay when compared to the parent compound. Subsequent reverse transcriptase 
PCR (RT-PCR) experiments showed that the mRNA level of the c-myc gene could be 
significantly diminished in the presence of complexes 7–9, suggesting that these compounds 
could be used as suppressors of oncogenic expressing in living cells. This report by Che and 
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co-workers again demonstrated the feasibility of in silico structure-based lead optimization 
of metal complexes, and suggested that the use of a larger chemical library of derivatives 
could generate a larger diversity of hits with potentially improved potencies. 
 
Figure 5. Chemical structures of the platinum(II) complexes discovered through in silico structure-
based optimization as c-myc oncogenic G-quadruplex stabilizing ligands. 
Our group has recently reported the structural-based optimization of FDA-approved drug 
methylene blue (MB) to generate more potent analogues as c-myc G-quadruplex stabilizers 
(Chan et al. 2011). Over 3,000 FDA-approved drugs were screened in silico against the 1:2:1 
loop isomer model of the c-myc G-quadruplex developed by our group, and MB emerged as 
the top candidate. Although the MB is a well-known DNA intercalator and has been 
previously reported to bind the G-quadruplex, its application as a c-myc oncogenic promoter 
G-quadruplex stabilizer was first discovered by our group. 50 MB derivatives were 
designed in silico and were docked against the c-myc G-quadruplex using ICM-Pro software. 
Compounds 10a–c bearing a bromophenyl pendant linked by an aliphatic side chain 
showed the greatest binding energy from the virtual screening, and they were synthesized 
for biological evaluation. In the fluorescence intercalator displacement (FID) assay, 
compound 10b was found to effectively displace thiazole orange (TO) from the c-myc G-
quadruplex with a DC50 value of 0.75 µM, while compounds 10a and 10c displayed higher 
DC50 values of ca. 6 and 2 µM, respectively. Furthermore, compound 10b could inhibit Taq 
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polymerase mediated-extension of the c-myc sequence through induction of the G-
quadruplex structure in the PCR stop assay with superior potency compared to the parent 
compound MB. Detailed molecular docking analysis revealed that compound 10b was 
predicted to form strong end-stacking interactions with the terminal of c-myc G-quadruplex 
with groove interactions, whereas the parent compound MB was predicted to interact with 
the G-quadruplex via a mostly intercalative mode. In living cells, compound 10b was shown 
to be effectively down-regulate the c-myc promoter activity with an IC50 value of ca. 1 µM as 
revealed by a luciferase assay. The increased activity of the 10b compared to MB against c-
myc promoter activity could be potentially attributed, at least in part, to the stabilization of 
c-myc G-quadruplex structure. This report demonstrated the structure-based lead 
optimization approach effectively generate novel analogues of existing drug as oncogenic G-
quadruplex stabilizing ligands. 
 
Figure 6. Chemical structures of the FDA-approved drug methylene blue and its analogues designed 
by a structural-based optimization strategy as c-myc oncogenic G-quadruplex stabilizing ligands. 
7. Conclusion 
The identification of oncogenes involved in the progression of various types of tumours has 
stimulated the development of various anti-cancer strategies targeting oncogenic 
expression. The discovery of G-quadruplex motifs in the promoter regions of oncogenes and 
the elucidation of their putative roles in the regulation of oncogenic transcription has 
opened a new potential therapeutic avenue for the treatment of cancer. However, it should 
be noted that the application of G-quadruplex-stabilizing ligands for the modulation of 
oncogenic activity in living systems is still in its infancy. Most promoter quadruplex ligands 
discovered thus far have not yet progressed past pre-clinical investigation. To advance 
further, several important criteria have to be addressed. These include the bioavailability of 
G-quadruplex-binding compounds as well their conformational rigidity and promiscuity for 
other physiological targets. In particular, the action of the lead candidates against the large 
number of other gene promoters and G‑quadruplex structures that are likely to be present 
in normal cells should be rigorously assessed. These factors would aid in the determination 
of the permissible dosage and therapeutic window of the G-quadruplex-targeting 
compounds for the potential treatment of cancer. With continual advances in computational 
technologies and modelling techniques, as well as the concurrent development of more 
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focused yet diverse chemical libraries, we envisage that the discovery and investigation of 
novel promoter G-quadruplex-stabilizing ligands would continue to thrive in the near 
future. Furthermore, in silico hit-to-lead optimization allows the chemical space around hit 
compounds to be explored without necessitating the actual synthesis of analogue molecules, 
thus significantly reducing expenses associated with materials and manpower. 
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